Ngā hua rapu - Arndt Vogel

Whakamahine hua
  1. 1
    Autoimmune Hepatitis, From Mechanisms to Therapy

    Autoimmune Hepatitis, From Mechanisms to Therapy mā Michael P. Manns, Arndt Vogel

    I whakaputaina 2006
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Epidemiology and Risk Factors of Cholangiocarcinoma

    Epidemiology and Risk Factors of Cholangiocarcinoma mā Martha M. Kirstein, Arndt Vogel

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next?

    FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next? mā Anna Saborowski, Ulrich Lehmann, Arndt Vogel

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis

    Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis mā Arndt Vogel, Christian P. Strassburg, Michael P. Manns

    I whakaputaina 2002
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    FGFR2 Inhibition in Cholangiocarcinoma

    FGFR2 Inhibition in Cholangiocarcinoma mā Arndt Vogel, Oreste Segatto, Albrecht Stenzinger, Anna Saborowski

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies

    Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies mā Arndt Vogel, Ralf‐Dieter Hofheinz, Stefan Kubicka, Dirk Arnold

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    The Diagnosis and Treatment of Cholangiocarcinoma

    The Diagnosis and Treatment of Cholangiocarcinoma mā Arndt Vogel, Henning Wege, Karel Caca, Björn Nashan, Ulf P. Neumann

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice

    Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice mā Ângelo Zambam de Mattos, Isadora Bombassaro, Arndt Vogel, José D. Debes

    I whakaputaina 2024
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab

    Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab mā Chiun Hsu, Lorenza Rimassa, Hui‐Chuan Sun, Arndt Vogel, Ahmed O. Kaseb

    I whakaputaina 2021
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma

    Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma mā Gajanan Kendre, Karthikeyan Murugesan, Tilman Brummer, Oreste Segatto, Anna Saborowski, Arndt Vogel

    I whakaputaina 2022
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Systemic Therapy of Advanced Hepatocellular Carcinoma

    Systemic Therapy of Advanced Hepatocellular Carcinoma mā Peter R. Galle, Jean‐François Dufour, Markus Peck‐Radosavljevic, Jörg Trojan, Arndt Vogel

    I whakaputaina 2020
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer

    UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer mā Johann Ockenga, Arndt Vogel, Niels Teich, Volker Keim, Michael P. Manns, Christian P. Strassburg

    I whakaputaina 2003
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data

    Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data mā Martha M. Kirstein, Ansgar Lange, Anne Prenzler, Michael P. Manns, Stefan Kubicka, Arndt Vogel

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing

    Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing mā Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, Ángela Lamarca, Paul Hofman, Luigi Terracciano, Nicola Normanno

    I whakaputaina 2023
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4

    Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4 mā Ursula Ehmer, Arndt Vogel, Jan Karl Schütte, B Krone, Michael P. Manns, Christian P. Strassburg

    I whakaputaina 2004
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Next-Generation Biomarkers for Cholangiocarcinoma

    Next-Generation Biomarkers for Cholangiocarcinoma mā Pedro M. Rodrigues, Arndt Vogel, Marco Arrese, Domingo Balderramo, Juan W. Valle, Jesús M. Bañales

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy

    Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy mā Ângelo Zambam de Mattos, José D. Debes, André Boonstra, Arndt Vogel, Ângelo Alves de Mattos

    I whakaputaina 2021
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up mā Florian Lordick, Fátima Carneiro, Stefano Cascinu, Tania Fleitas, Karin Haustermans, Guillaume Piessen, Arndt Vogel, Elizabeth Smyth

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

    Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines mā Arndt Vogel, Erika Martinelli, Arndt Vogel, Andrés Cervantes, Ian Chau, Bruno Daniele, Josep M. Llovet, Tim Meyer, Jean‐Charles Nault, Ulf P. Neumann, Jens Ricke, Bruno Sangro, Peter Schirmacher, Chris Verslype, Francis Zech, Dirk Arnold, Erika Martinelli

    I whakaputaina 2021
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer

    A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer mā Ansgar Lange, Anne Prenzler, Martin Frank, Martha M. Kirstein, Arndt Vogel, Johann‐Matthias Graf von der Schulenburg

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: